BHWM
JAZZ icon

Beaird Harris Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Beaird Harris Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123 Hold
1
– – ﹤0.01% 678
2026
Q1 		$97 Hold
1
– – ﹤0.01% 659
2025
Q4 		$87 Hold
1
– – ﹤0.01% 684
2025
Q3 		$68 Buy
+1
New +$120 ﹤0.01% 712
2023
Q1 		– Sell
-105
Closed -$16.7K – 605
2022
Q4 		$16.7K Buy
+105
New +$15.4K ﹤0.01% 277

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Beaird Harris Wealth Management's JAZZ Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 1 share worth $123. The position accounts for ﹤0.01% of the portfolio, ranked #678.

Beaird Harris Wealth Management first reported a position in JAZZ in Q4 2022 and has held it in 5 quarters since. The position peaked at $16.7K in Q4 2022. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Beaird Harris Wealth Management held 1 share of Jazz Pharmaceuticals worth $123 as of Q2 2026.
  • Beaird Harris Wealth Management left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #678 holding.
  • Beaird Harris Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
  • Beaird Harris Wealth Management's Jazz Pharmaceuticals position peaked at $16.7K in Q4 2022.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.